Drug Trial Radar · NCT07390747
A Trial of SHR-2173 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Mar 6, 2026
Primary completion
May 22, 2026
Study completion Sep 28, 2026
Sponsor
- Lead sponsor
- Atridia Pty Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Single group
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess safety, PK, Pharmacodynamic and immunogenicity profile of a single dose of SHR-2173 in healthy participants
Conditions
- Immunology
Interventions
SHR-2173 Injection/SHR-2173 placeboDrug
Single dose SHR-2173 injection or matching placebo given subcutaneously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics - CmaxTime frame: Day 71
- Pharmacokinetics - AUC₀-tTime frame: Day 71
- Pharmacokinetics - AUC₀-infTime frame: Day 71
- Pharmacokinetics - TmaxTime frame: Day 71
- Pharmacokinetics - t½Time frame: Day 71
- Immunogenicity - Anti-Drug Antibody (ADA)Time frame: Day 71
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Veritus Research
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.